C4 Therapeutics, Inc. (CCCC) Institutional Ownership

Ownership Summary

C4 Therapeutics, Inc. (NASDAQ:CCCC) currently has 97 active institutional owners and shareholders as of today (September 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• The percentage of C4 Therapeutics owned by institutions changed from 77.1% in June 2025 to 73.9% in September 2025, marking a slight down trend.
• The company experienced a -4.19% quarterly change in institutional shares held, alongside a decrease of 17.09% in total owners annually.
• Of these 97 institutional investors, 44 increased their holdings in C4 Therapeutics, while 41 of them reduced positions, and 12 investors maintained their exposure.
• The total number of shares held by institutions in C4 Therapeutics decreased to 52.62Mn as of September 2025, a net change of down by 2.30Mn shares quarter on quarter, and down 10.76Mn shares year over year.
• Lynx1 Capital Management LP's holding of 7.10Mn shares as of September 30, 2025 makes it the primary institutional investor in C4 Therapeutics, owning 9.97% of the stock.
• Among the most significant buyers of C4 Therapeutics during September 2025 were SILVERARC CAPITAL MANAGEMENT, LLC (1.02Mn), MILLENNIUM MANAGEMENT LLC (922.88K), CITADEL ADVISORS LLC (452.83K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (374.38K), Shay Capital LLC (326.59K).
• Leading sellers of C4 Therapeutics stock in September 2025 included WASATCH ADVISORS LP (2.57Mn), ORBIMED ADVISORS LLC (1.60Mn), UBS Group AG (510.38K), GOLDMAN SACHS GROUP INC (420.37K), JANE STREET GROUP, LLC (289.04K).
• The top 10 institutional holders of C4 Therapeutics for the quarter ending September 2025 included Lynx1 Capital Management LP (7.10Mn), Soleus Capital Management, L.P. (7.05Mn), ORBIMED ADVISORS LLC (5.24Mn), MORGAN STANLEY (4.97Mn), WASATCH ADVISORS LP (4.85Mn), VANGUARD GROUP INC (3.19Mn), BANK OF AMERICA CORP /DE/ (2.05Mn), MILLENNIUM MANAGEMENT LLC (2.02Mn), SILVERARC CAPITAL MANAGEMENT, LLC (1.90Mn), BlackRock, Inc. (1.60Mn).